Re: Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial (Ophthalmology 2016;123:141-153)

José Estevez, Konrad Pesudovs

    Research output: Contribution to journalLetterpeer-review

    Abstract

    To the Editor:

    We read with interest the article by Pinto-Fraga et al.1 They examined a group of patients with moderate to severe dry eye disease (DED) treated with corticosteroids or polyvinyl alcohol for 3 weeks. The authors concluded that fluoromethalone 0.1% (FML, Allergan, Inc., Irvine, CA) topical eye drops maintained the ocular surface status of DED patients after an exposure to an “adverse environment.” Subjects treated with polyvinyl alcohol vehicle (Liquifilm Tears, Allergan) as the control were significantly impaired by the “adverse environment.” Additionally, the authors concluded that the 3-week course of topical FML 0.1% was safe for DED patients as there were no reported adverse events.
    Original languageEnglish
    Pages (from-to)e14
    Number of pages1
    JournalOphthalmology
    Volume124
    Issue number2
    DOIs
    Publication statusPublished - Feb 2017

    Keywords

    • fluorometholone therapy
    • dry eye disease (DED)
    • Ocular surface inflammation
    • dessicating stress
    • Corneal staining

    Fingerprint

    Dive into the research topics of 'Re: Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial (Ophthalmology 2016;123:141-153)'. Together they form a unique fingerprint.

    Cite this